间质性肺疾病急性加重研究进展OA
Research progress on acute exacerbation of interstitial lung disease
间质性肺疾病急性加重(AE-ILD)患者病情危重且进展迅速,严重影响患者的生存和预后.发病机制方面,肺泡上皮Ⅱ型细胞(AEC2)程序性凋亡的异常激活、免疫炎症级联反应及细胞外基质(ECM)稳态失衡等关键环节可能导致AE-ILD.生物标记物和临床预测模型为AE-ILD的早期预警及预后评估提供了重要工具.临床诊疗方面,本文梳理了 AE-ILD诊疗策略的最新共识与突破,多项临床试验的开展为探索AE-ILD生存获益的治疗方法奠定了基础.随着发病机制的深入阐明、生物标志物的整合应用以及预测模型的优化,AE-ILD的防治将进入新阶段.
Patients with acute exacerbation of interstitial lung disease(AE-ILD)are critically ill and experience rapid disease progression,which significantly impacts their survival and prognosis.In terms of pathogenesis,key factors such as the abnormal activation of programmed apoptosis in alveolar epithelial type Ⅱ cells(AEC2),immune-inflammatory cascade reactions,and extracellular matrix(ECM)homeostasis imbalance may contribute to AE-ILD.Biomarkers and clinical prediction models provide important tools for early warning and prognosis assessment of AE-ILD.Regarding clinical di-agnosis and treatment,this paper reviewed the latest consensus and breakthroughs in the diagnostic and therapeutic strategies for AE-ILD.The implementation of multiple clinical trials has laid the foun-dation for exploring treatment methods that offer survival benefits for AE-ILD.With the in-depth elu-cidation of pathogenesis,the integrated application of biomarkers,and the optimization of prediction models,the prevention and treatment of AE-ILD will enter a new stage.
侯仕璇;陈敏;曹孟淑
南京大学医学院附属鼓楼医院呼吸与危重症医学科,江苏南京,210008南京中医药大学鼓楼临床医学院呼吸与危重症医学科,江苏南京,210008南京大学医学院附属鼓楼医院呼吸与危重症医学科,江苏南京,210008||南京中医药大学鼓楼临床医学院呼吸与危重症医学科,江苏南京,210008
医药卫生
间质性肺疾病急性加重肺泡上皮Ⅱ型细胞程序性细胞死亡免疫炎症反应细胞外基质稳态生物标志物糖皮质激素抗纤维化药
acute exacerbation of interstitial lung diseasealveolar epithelial type Ⅱ cellspro-grammed cell deathimmune-inflammatory responseextracellular matrix homeostasisbiomarkersglucocorticoidsantifibrotic drugs
《实用临床医药杂志》 2026 (6)
140-143,148,5
国家自然科学基金项目(82570105)
评论